269 related articles for article (PubMed ID: 30946948)
1. Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug.
Zhang X; Selvaraju K; Saei AA; D'Arcy P; Zubarev RA; Arnér ES; Linder S
Biochimie; 2019 Jul; 162():46-54. PubMed ID: 30946948
[TBL] [Abstract][Full Text] [Related]
2. Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth.
Liu N; Li X; Huang H; Zhao C; Liao S; Yang C; Liu S; Song W; Lu X; Lan X; Chen X; Yi S; Xu L; Jiang L; Zhao C; Dong X; Zhou P; Li S; Wang S; Shi X; Dou PQ; Wang X; Liu J
Oncotarget; 2014 Jul; 5(14):5453-71. PubMed ID: 24977961
[TBL] [Abstract][Full Text] [Related]
3. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells.
Chitta K; Paulus A; Akhtar S; Blake MK; Caulfield TR; Novak AJ; Ansell SM; Advani P; Ailawadhi S; Sher T; Linder S; Chanan-Khan A
Br J Haematol; 2015 May; 169(3):377-90. PubMed ID: 25691154
[TBL] [Abstract][Full Text] [Related]
4. Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress.
Brnjic S; Mazurkiewicz M; Fryknäs M; Sun C; Zhang X; Larsson R; D'Arcy P; Linder S
Antioxid Redox Signal; 2014 Dec; 21(17):2271-85. PubMed ID: 24011031
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
D'Arcy P; Brnjic S; Olofsson MH; Fryknäs M; Lindsten K; De Cesare M; Perego P; Sadeghi B; Hassan M; Larsson R; Linder S
Nat Med; 2011 Nov; 17(12):1636-40. PubMed ID: 22057347
[TBL] [Abstract][Full Text] [Related]
6. Cadmium pyrithione suppresses tumor growth in vitro and in vivo through inhibition of proteasomal deubiquitinase.
Chen X; Wu J; Yang Q; Zhang X; Zhang P; Liao S; He Z; Wang X; Zhao C; Liu J
Biometals; 2018 Feb; 31(1):29-43. PubMed ID: 29098502
[TBL] [Abstract][Full Text] [Related]
7. The deubiquitinase inhibitor b-AP15 induces strong proteotoxic stress and mitochondrial damage.
Zhang X; Pellegrini P; Saei AA; Hillert EK; Mazurkiewicz M; Olofsson MH; Zubarev RA; D'Arcy P; Linder S
Biochem Pharmacol; 2018 Oct; 156():291-301. PubMed ID: 30149015
[TBL] [Abstract][Full Text] [Related]
8. The 19S Deubiquitinase inhibitor b-AP15 is enriched in cells and elicits rapid commitment to cell death.
Wang X; Stafford W; Mazurkiewicz M; Fryknäs M; Brjnic S; Zhang X; Gullbo J; Larsson R; Arnér ES; D'Arcy P; Linder S
Mol Pharmacol; 2014 Jun; 85(6):932-45. PubMed ID: 24714215
[TBL] [Abstract][Full Text] [Related]
9. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
Tian Z; D'Arcy P; Wang X; Ray A; Tai YT; Hu Y; Carrasco RD; Richardson P; Linder S; Chauhan D; Anderson KC
Blood; 2014 Jan; 123(5):706-16. PubMed ID: 24319254
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia.
Talbot S; Nelson R; Self WT
Br J Pharmacol; 2008 Jul; 154(5):940-8. PubMed ID: 18587442
[TBL] [Abstract][Full Text] [Related]
11. Potential Anticancer Activity of Auranofin.
Onodera T; Momose I; Kawada M
Chem Pharm Bull (Tokyo); 2019; 67(3):186-191. PubMed ID: 30827998
[TBL] [Abstract][Full Text] [Related]
12. A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy.
Zhao C; Chen X; Zang D; Lan X; Liao S; Yang C; Zhang P; Wu J; Li X; Liu N; Liao Y; Huang H; Shi X; Jiang L; Liu X; He Z; Dou QP; Wang X; Liu J
Oncogene; 2016 Nov; 35(45):5916-5927. PubMed ID: 27086925
[TBL] [Abstract][Full Text] [Related]
13. Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases.
Zhao C; Chen X; Yang C; Zang D; Lan X; Liao S; Zhang P; Wu J; Li X; Liu N; Liao Y; Huang H; Shi X; Jiang L; Liu X; Dou QP; Wang X; Liu J
Oncotarget; 2017 Feb; 8(8):13942-13956. PubMed ID: 28086217
[TBL] [Abstract][Full Text] [Related]
14. [Potential Anticancer Activity of Auranofin].
Momose I; Onodera T; Kawada M
Yakugaku Zasshi; 2021; 141(3):315-321. PubMed ID: 33642497
[TBL] [Abstract][Full Text] [Related]
15. Oxidative Stress Induced by the Deubiquitinase Inhibitor b-AP15 Is Associated with Mitochondrial Impairment.
Zhang X; Espinosa B; Saei AA; D'Arcy P; Zubarev RA; Linder S
Oxid Med Cell Longev; 2019; 2019():1659468. PubMed ID: 31281566
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of thioredoxin reductase and proteasome is required for auranofin-induced paraptosis in breast cancer cells.
Seo MJ; Kim IY; Lee DM; Park YJ; Cho MY; Jin HJ; Choi KS
Cell Death Dis; 2023 Jan; 14(1):42. PubMed ID: 36658130
[TBL] [Abstract][Full Text] [Related]
17. A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.
Liu N; Liu C; Li X; Liao S; Song W; Yang C; Zhao C; Huang H; Guan L; Zhang P; Liu S; Hua X; Chen X; Zhou P; Lan X; Yi S; Wang S; Wang X; Dou QP; Liu J
Sci Rep; 2014 Jun; 4():5240. PubMed ID: 24912524
[TBL] [Abstract][Full Text] [Related]
18. The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells.
Schmidt M; Altdörfer V; Schnitte S; Fuchs AR; Kropp KN; Maurer S; Müller MR; Salih HR; Rittig SM; Grünebach F; Dörfel D
Neoplasia; 2019 Jul; 21(7):653-664. PubMed ID: 31132676
[TBL] [Abstract][Full Text] [Related]
19. Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Redox Biol; 2016 Aug; 8():175-85. PubMed ID: 26795735
[TBL] [Abstract][Full Text] [Related]
20. Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells.
Sachweh MC; Stafford WC; Drummond CJ; McCarthy AR; Higgins M; Campbell J; Brodin B; Arnér ES; Laín S
Oncotarget; 2015 Jun; 6(18):16488-506. PubMed ID: 26029997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
